ERYP
NASDAQErytech Pharma S.A.
Latest news
25 items- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 424B3 filed by Erytech Pharma S.A.424B3 - PHAXIAM Therapeutics S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - Erytech Pharma S.A. (0001624422) (Filer)
- NEWSERYTECH Announces The Approval Of The Merger With Pherecydes And Reports The Results Of The Combined Shareholder's Meeting Held On June 23, 2023All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy
- PRERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma ((Euronext Paris &, NASDAQ:ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023 The adopted resolutio
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - Erytech Pharma S.A. (0001624422) (Filer)
- PRERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuitERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (NASDAQ:ERYP) announces the filing of a new lawsuit by Akkadian Partners. Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech. As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capit
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - Erytech Pharma S.A. (0001624422) (Filer)
- NEWSErytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes CloserIn February, Erytech Pharma SA (NASDAQ:ERYP) announced its proposed combination with Pherecydes Pharma S.A. In June, Erytech announced that Akkadian initiated proceedings to postpone the vote, scheduled on 23 June, on the merger with Pherecydes. The merger would see Pherecydes absorbed into publicly listed Erytech, with Pherecydes shareholders receiving 15 new Erytech shares for every four of their current shares. Monday, Erytech Pharma responded to what it described as Akkadian Partners' "disinformation," arguing that the investor's challenge to the merger was "based on incomplete information and misleading arguments." Akkadian Partners owns around 5% of Erytech's stock. Erytech warned
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - Erytech Pharma S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - Erytech Pharma S.A. (0001624422) (Filer)
- SECSEC Form 6-K filed by Erytech Pharma S.A.6-K - Erytech Pharma S.A. (0001624422) (Filer)
- SECSEC Form F-X filed by Erytech Pharma S.A.F-X - Erytech Pharma S.A. (0001624422) (Subject)
- SECSEC Form CB filed by Erytech Pharma S.A.CB - Erytech Pharma S.A. (0001624422) (Subject)
ERYP FAQ
6 questionsWhat does Erytech Pharma S.A. do?
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target...Where does ERYP stock trade?
Erytech Pharma S.A. (ERYP) is listed on NASDAQ.What sector and industry is ERYP in?
Erytech Pharma S.A. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Erytech Pharma S.A. go public?
Erytech Pharma S.A. (ERYP) completed its IPO in 2017.What companies are similar to ERYP?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ERYP side-by-side with any of them on Quantisnow.How can I track ERYP on Quantisnow?
Quantisnow aggregates Erytech Pharma S.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ERYP to receive live email and push alerts on every new disclosure.